secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001193125-22-289487
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva appoints Richard Francis as President and CEO effective Jan 1, 2023; Kåre Schultz to retire Dec 31, 2022
--------------------------------------------------------------------------------

- Francis to receive $1.6M base salary, 150% target bonus, and $9M annual equity (70% PSU, 30% RSU).
- Sign-on awards: $5M RSU (3-year vesting), $5M PSU (stretch goals), and $5M cash (3 installments).
- Schultz to remain CEO through Dec 31, then on garden leave until Feb 19, 2023; treated as termination without cause.
- Francis previously CEO of Sandoz (2014-2019) and senior exec at Biogen overseeing Tecfidera launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/0001193125-22-289487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/d284218d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-289487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer